Start-up Studios

As an integral component of our multi-pronged BRIDGE partnerships, Evotec has initiated and invested into selected Startup Studios in Europe and North America which are aiming to accelerate the validation and commercialization of early-stage drug discovery concepts from top-tier academic researchers.

In June 2020, Evotec announced the launch of “Autobahn-Labs”, a novel virtual incubator, together with Samsara BioCapital, a leading life sciences investment firm and KCK Ltd., a family investment fund. Based out of the San Francisco Bay Area, Autobahn-Labs has been partnering with top academic and research institutions to catalyse early-stage drug discovery and development.

In March 2021, the launch of Argobio was announced. Argobio is a start-up studio dedicated to life sciences which was initiated by Kurma Partners, a leading Paris and Munich-based healthcare venture capital firm, Bpifrance, the French national investment bank, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, internationally renowned center for biomedical research.

In October 2022, Evotec announced the launch of Extend, a translational BRIDGE in cooperation with CDP Venture Capital Sgr and Angelini Ventures, the Corporate Venture arm of the multi-business industrial group Angelini Industries. The Milan-based joint venture is developing translational drug discovery partnerships with renowned universities and research centers in Italy.